Nanocarriers for Brain Targeting: Overcoming the Blood-Brain Barrier in Neuropharmacology
Abstract
The blood-brain barrier (BBB) is a highly selective physiological barrier that protects the central nervous system from harmful substances while maintaining brain homeostasis. However, the BBB significantly limits the delivery of therapeutic agents to the brain, creating major challenges in the treatment of neurological disorders. Conventional drug delivery systems often fail to achieve sufficient drug concentrations in brain tissues due to poor permeability, enzymatic degradation, and systemic elimination. Nanocarrier-based drug delivery systems have emerged as a promising strategy to overcome BBB-related limitations and improve targeted brain delivery. Nanocarriers such as liposomes, polymeric nanoparticles, dendrimers, solid lipid nanoparticles, nanoemulsions, metallic nanoparticles, and polymeric micelles offer enhanced drug stability, improved bioavailability, prolonged circulation time, controlled drug release, and targeted delivery to diseased brain tissues. These systems can cross the BBB through receptor-mediated transcytosis, adsorptive-mediated transcytosis, carrier-mediated transport, and temporary BBB modulation. Surface modification with ligands, peptides, antibodies, and polymers further enhances targeting efficiency and therapeutic outcomes. Nanocarrier-based approaches have shown promising applications in Alzheimer’s disease, Parkinson’s disease, epilepsy, stroke, multiple sclerosis, and brain tumours. Despite substantial progress, challenges related to toxicity, immunogenicity, scalability, regulatory approval, and long-term safety remain significant concerns. This review discusses the structure and functions of the BBB, mechanisms of nanocarrier transport across the BBB, different classes of nanocarriers, therapeutic applications in neuropharmacology, recent advancements, current limitations, and future perspectives in brain-targeted nanomedicine.
Keywords: Blood-brain barrier, Nanocarriers, Brain targeting, Neuropharmacology, Nanomedicine, Nanoparticles, Drug delivery systems
Keywords:
Blood-brain barrier, Nanocarriers, Brain targeting, Neuropharmacology, Nanomedicine, Nanoparticles, Drug delivery systemsDOI
https://doi.org/10.22270/jddt.v16i6.7777References
1. Ahlawat J, Guillama Barroso G, Masoudi Asil S, Alvarado M, Armendariz I, Bernal J, Carabaza X, Chavez S, Cruz P, Escalante V, Estorga S. Nanocarriers as potential drug delivery candidates for overcoming the blood-brain barrier: challenges and possibilities. ACS omega. 2020 Jun 1;5(22):12583-95. https://doi.org/10.1021/acsomega.0c01592 PMid:32548442 PMCid:PMC7288355
2. Kreuter J. Transport of drugs across the blood-brain barrier by nanoparticles. Current Medicinal Chemistry-Central Nervous System Agents. 2002 Sep 1;2(3):241-9. https://doi.org/10.2174/1568015023357950
3. Mulvihill JJ, Cunnane EM, Ross AM, Duskey JT, Tosi G, Grabrucker AM. Drug delivery across the blood-brain barrier: recent advances in the use of nanocarriers. Nanomedicine. 2020 Jan 1;15(2):205-14. https://doi.org/10.2217/nnm-2019-0367 PMid:31916480
4. Patel V, Chavda V, Shah J. Nanotherapeutics in neuropathologies: obstacles, challenges and recent advancements in CNS targeted drug delivery systems. Current Neuropharmacology. 2021 May 1;19(5):693-710. PMid:32851949 PMCid:PMC8573747 https://doi.org/10.2174/1570159X18666200807143526
5. Benz F, Liebner S. Structure and function of the blood-brain barrier (BBB). InPhysiology, pharmacology and pathology of the blood-brain barrier 2020 Nov 29 (pp. 3-31). Cham: Springer International Publishing. https://doi.org/10.1007/164_2020_404 PMid:33249527
6. Ballabh P, Braun A, Nedergaard M. The blood-brain barrier: an overview: structure, regulation, and clinical implications. Neurobiology of disease. 2004 Jun 1;16(1):1-3. https://doi.org/10.1016/j.nbd.2003.12.016 PMid:15207256
7. Begley DJ, Brightman MW. Structural and functional aspects of the blood-brain barrier. Peptide transport and delivery into the central nervous system. 2003 Jan 1:39-78. https://doi.org/10.1007/978-3-0348-8049-7_2 PMid:14674608
8. Correale J, Villa A. Cellular elements of the blood-brain barrier. Neurochemical research. 2009 Dec;34(12):2067-77. https://doi.org/10.1007/s11064-009-0081-y PMid:19856206
9. Chow BW, Gu C. The molecular constituents of the blood-brain barrier. Trends in neurosciences. 2015 Oct 1;38(10):598-608. https://doi.org/10.1016/j.tins.2015.08.003 PMid:26442694 PMCid:PMC4597316
10. Norsted E, Gömüç B, Meister B. Protein components of the blood-brain barrier (BBB) in the mediobasal hypothalamus. Journal of chemical neuroanatomy. 2008 Oct 1;36(2):107-21. https://doi.org/10.1016/j.jchemneu.2008.06.002 PMid:18602987
11. Banks WA, Erickson MA. The blood-brain barrier and immune function and dysfunction. Neurobiology of disease. 2010 Jan 1;37(1):26-32. https://doi.org/10.1016/j.nbd.2009.07.031 PMid:19664708
12. Blanchette M, Daneman R. Formation and maintenance of the BBB. Mechanisms of development. 2015 Nov 1;138:8-16. https://doi.org/10.1016/j.mod.2015.07.007 PMid:26215350
13. Pollay M, Roberts PA. Blood-brain barrier: a definition of normal and altered function. Neurosurgery. 1980 Jun 1;6(6):675-85. https://doi.org/10.1227/00006123-198006000-00014 PMid:7001265
14. Krol S. Challenges in drug delivery to the brain: nature is against us. Journal of Controlled Release. 2012 Dec 10;164(2):145-55. https://doi.org/10.1016/j.jconrel.2012.04.044 PMid:22609350
15. Abbott NJ. Blood-brain barrier structure and function and the challenges for CNS drug delivery. Journal of inherited metabolic disease. 2013 May;36(3):437-49. https://doi.org/10.1007/s10545-013-9608-0 PMid:23609350
16. Bors LA, Erdő F. Overcoming the blood-brain barrier. challenges and tricks for CNS drug delivery. Scientia Pharmaceutica. 2019;87(1):6. https://doi.org/10.3390/scipharm87010006
17. Mulvihill JJ, Cunnane EM, Ross AM, Duskey JT, Tosi G, Grabrucker AM. Drug delivery across the blood-brain barrier: recent advances in the use of nanocarriers. Nanomedicine. 2020 Jan 1;15(2):205-14. https://doi.org/10.2217/nnm-2019-0367 PMid:31916480
18. Comoglu T, Arisoy S, Burcu Akkus Z. Nanocarriers for effective brain drug delivery. Current Topics in Medicinal Chemistry. 2017 May 1;17(13):1490-506. https://doi.org/10.2174/1568026616666161222101355 PMid:28017157
19. Lai F, Fadda AM, Sinico C. Liposomes for brain delivery. Expert opinion on drug delivery. 2013 Jul 1;10(7):1003-22. https://doi.org/10.1517/17425247.2013.766714 PMid:23373728
20. Bhatt N. Drug delivery to the brain using polymeric nanoparticles: a review. International journal of pharmaceutical and life science. 2013 Jun 24.
21. Satapathy MK, Yen TL, Jan JS, Tang RD, Wang JY, Taliyan R, Yang CH. Solid lipid nanoparticles (SLNs): an advanced drug delivery system targeting brain through BBB. Pharmaceutics. 2021 Jul 31;13(8):1183. PMid:34452143 PMCid:PMC8402065 https://doi.org/10.3390/pharmaceutics13081183
22. Uppar AL, Patil CC, Namannavar S, Deshmane PA. Formulation and Evaluation of Caffeine-Loaded Cubosomes Hydrogel for Topical Delivery. Journal of Drug Delivery & Therapeutics. 2026 Apr 1;16(4):39. https://doi.org/10.22270/jddt.v16i4.7666
23. Zhu Y, Liu C, Pang Z. Dendrimer-based drug delivery systems for brain targeting. Biomolecules. 2019 Nov 27;9(12):790. https://doi.org/10.3390/biom9120790 PMid:31783573 PMCid:PMC6995517
24. L. Shinde R, B. Jindal A, V. Devarajan P. Microemulsions and nanoemulsions for targeted drug delivery to the brain. Current Nanoscience. 2011 Feb 1;7(1):119-33. https://doi.org/10.2174/157341311794480282
25. Kreuter J. Mechanism of polymeric nanoparticle-based drug transport across the blood-brain barrier (BBB). Journal of microencapsulation. 2013 Feb 1;30(1):49-54. https://doi.org/10.3109/02652048.2012.692491 PMid:22676632
26. Sharma S, Dang S. Nanocarrier-based drug delivery to brain: interventions of surface modification. Current neuropharmacology. 2023 Mar 1;21(3):517-35. https://doi.org/10.2174/1570159X20666220706121412 PMid:35794771 PMCid:PMC10207924
27. Rajput A, Pingale P, Dhapte-Pawar V. Nasal delivery of neurotherapeutics via nanocarriers: Facets, aspects, and prospects. Frontiers in pharmacology. 2022 Sep 13;13:979682. https://doi.org/10.3389/fphar.2022.979682 PMid:36176429 PMCid:PMC9513345
28. Mittal KR, Pharasi N, Sarna B, Singh M, Rachana, Haider S, Singh SK, Dua K, Jha SK, Dey A, Ojha S. Nanotechnology-based drug delivery for the treatment of CNS disorders. Translational Neuroscience. 2022 Dec 31;13(1):527-46. https://doi.org/10.1515/tnsci-2022-0258 PMid:36741545 PMCid:PMC9883694
29. Ayub A, Wettig S. An overview of nanotechnologies for drug delivery to the brain. Pharmaceutics. 2022 Jan 19;14(2):224. https://doi.org/10.3390/pharmaceutics14020224 PMid:35213957 PMCid:PMC8875260
30. Liu S, Tan B, Wang F, Yu Y. Applications of polymeric nanoparticles in drug delivery for glioblastoma. Frontiers in Pharmacology. 2025 Jan 6;15:1519479. PMCid:PMC11742935 https://doi.org/10.3389/fphar.2024.1519479 PMid:39834835
31. Al-Hamadiny S, Salman R, Al-Rawe A. Nanocarriers and beyond: Innovations in overcoming barriers for effective CNS drug delivery. Trends in Pharmaceutical Biotechnology. 2023 Jun 30;1(1):34-47. https://doi.org/10.57238/tpb.2023.144275.1003
32. Maher R, Moreno-Borrallo A, Jindal D, Mai BT, Ruiz-Hernandez E, Harkin A. Intranasal polymeric and lipid-based nanocarriers for CNS drug delivery. Pharmaceutics. 2023 Mar;15(3):746. https://doi.org/10.3390/pharmaceutics15030746 PMid:36986607 PMCid:PMC10051709
33. Bennet D, Kim S. Polymer nanoparticles for smart drug delivery. Application of nanotechnology in drug delivery. 2014 Jul 25;8:257-310. https://doi.org/10.5772/58422
34. Meng J, Agrahari V, Youm I. Advances in targeted drug delivery approaches for the central nervous system tumors: the inspiration of nanobiotechnology. Journal of Neuroimmune Pharmacology. 2017 Mar;12(1):84-98. https://doi.org/10.1007/s11481-016-9698-1 PMid:27449494
35. Tang S, Wang A, Yan X, Chu L, Yang X, Song Y, Sun K, Yu X, Liu R, Wu Z, Xue P. Brain-targeted intranasal delivery of dopamine with borneol and lactoferrin co-modified nanoparticles for treating Parkinson’s disease. Drug delivery. 2019 Jan 1;26(1):700-7. https://doi.org/10.1080/10717544.2019.1636420 PMid:31290705 PMCid:PMC7577045
36. Zou LL, Ma JL, Wang T, Yang TB, Liu CB. Cell-penetrating peptide-mediated therapeutic molecule delivery into the central nervous system. Current neuropharmacology. 2013 Mar 1;11(2):197-208. https://doi.org/10.2174/1570159X11311020006 PMid:23997754 PMCid:PMC3637673
37. Patel MM, Goyal BR, Bhadada SV, Bhatt JS, Amin AF. Getting into the brain: approaches to enhance brain drug delivery. CNS drugs. 2009 Jan;23(1):35-58. https://doi.org/10.2165/0023210-200923010-00003 PMid:19062774
38. Bajracharya R, Song JG, Patil BR, Lee SH, Noh HM, Kim DH, Kim GL, Seo SH, Park JW, Jeong SH, Lee CH. Functional ligands for improving anticancer drug therapy: current status and applications to drug delivery systems. Drug Delivery. 2022 Dec 31;29(1):1959-70. https://doi.org/10.1080/10717544.2022.2089296 PMid:35762636 PMCid:PMC9246174
39. Parvez S, Pathrathota A, Uppar AL, Yadagiri G, Mudavath SL. Influenza virus: global health impact, strategies, challenges, role of nanotechnolgy in influenza vaccine development. Vaccines. 2025 Aug 22;13(9):890. https://doi.org/10.3390/vaccines13090890 PMid:41012096 PMCid:PMC12474260
40. Kou L, Bhutia YD, Yao Q, He Z, Sun J, Ganapathy V. Transporter-guided delivery of nanoparticles to improve drug permeation across cellular barriers and drug exposure to selective cell types. Frontiers in pharmacology. 2018 Jan 26;9:27. https://doi.org/10.3389/fphar.2018.00027 PMid:29434548 PMCid:PMC5791163
41. Li C, Zhou L, Yin X. Pathophysiological aspects of transferrin-A potential nano-based drug delivery signaling molecule in therapeutic target for varied diseases. Frontiers in pharmacology. 2024 Mar 4;15:1342181. https://doi.org/10.3389/fphar.2024.1342181 PMid:38500764 PMCid:PMC10944884
42. Karthivashan G, Ganesan P, Park SY, Kim JS, Choi DK. Therapeutic strategies and nano-drug delivery applications in management of ageing Alzheimer’s disease. Drug delivery. 2018 Jan 1;25(1):307-20. https://doi.org/10.1080/10717544.2018.1428243 PMid:29350055 PMCid:PMC6058502
43. Lee Bredlau A, Dixit S, Chen C, Broome AM. Nanotechnology applications for diffuse intrinsic pontine glioma. Current neuropharmacology. 2017 Jan 1;15(1):104-15. https://doi.org/10.2174/1570159X14666160223121002 PMid:26903150 PMCid:PMC5327462
44. Emilian Leucuta S. Nanotechnology for delivery of drugs and biomedical applications. Current clinical pharmacology. 2010 Nov 1;5(4):257-80. https://doi.org/10.2174/157488410793352003 PMid:20925643
Published
Abstract Display: 0 
PDF Downloads: 0 PDF Downloads: 0 How to Cite
Issue
Section
Copyright (c) 2026 H V Nishanth , S Tejaswini, Sharuq Devoor, Calvin Joyson, H M Sneha, K Spoorthi, K M Laharika , Hemanth Kumar Dasappa
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
How to Cite
.